

## REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH HEART FAILURE CHRONIC

1. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR et al: **2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure**. *Journal of the American College of Cardiology* 2022, 79(17):e263-e421.
2. Maddox TM, Januzzi JL, Jr., Allen LA, Breathett K, Butler J, Davis LL, Fonarow GC, Ibrahim NE, Lindenfeld J, Masoudi FA et al: **2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee**. *J Am Coll Cardiol* 2021, 77(6):772-810.
3. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O et al: **2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure**. *Eur Heart J* 2021, 42(36):3599-3726.
4. McDonald M, Virani S, Chan M, Ducharme A, Ezekowitz JA, Giannetti N, Heckman GA, Howlett JG, Koshman SL, Lepage S et al: **CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction**. *Can J Cardiol* 2021, 37(4):531-546.
5. Ezekowitz JA, O'Meara E, McDonald MA, Abrams H, Chan M, Ducharme A, Giannetti N, Grzeslo A, Hamilton PG, Heckman GA et al: **2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure**. *Can J Cardiol* 2017, 33(11):1342-1433.
6. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM et al: **2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America**. *Circulation* 2017.
7. Atherton JJ, Sindone A, De Pasquale CG, Driscoll A, MacDonald PS, Hopper I, Kistler P, Briffa TG, Wong J, Abhayaratna WP et al: **National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart failure 2018**. *The Medical journal of Australia* 2018.
8. NICE: **Chronic heart failure in adults: diagnosis and management**. In: *NICE guideline*. 2018.
9. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC et al: **Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction**. *New England Journal of Medicine* 1992, 327(10):669-677.
10. Swedberg K, Kjeksus J: **Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)**. *The American Journal of Cardiology* 1988, 62(2):60A-66A.
11. Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliassen P, Lyngborg K, Videbæk J, Cole DS, Auclert L, Pauly NC et al: **A Clinical Trial of the Angiotensin-Converting-Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial Infarction**. *New England Journal of Medicine* 1995, 333(25):1670-1676.

12. **Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure.** *New England Journal of Medicine* 1991, **325**(5):293-302.
13. Garg R, Yusuf S, Bussmann WD, et al.: **Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure.** *JAMA* 1995, **273**(18):1450-1456.
14. **Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection Fractions.** *New England Journal of Medicine* 1992, **327**(10):685-691.
15. The Acute Infarction Ramipril Efficacy Study I: **Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure.** *The Lancet* 1993, **342**(8875):821-828.
16. **Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).** *The New England journal of medicine* 1987, **316**(23):1429-1435.
17. Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN: **Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.** *The New England journal of medicine* 1991, **325**(5):293-302.
18. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF: **Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.** *Circulation* 1999, **100**(23):2312-2318.
19. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moya L *et al*: **Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group.** *Lancet (London, England)* 2000, **355**(9215):1575-1581.
20. Ambrosioni E, Borghi C, Magnani B: **The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators.** *The New England journal of medicine* 1995, **332**(2):80-85.
21. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H *et al*: **Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.** *The New England journal of medicine* 2003, **349**(20):1893-1906.
22. Cohn JN, Tognoni G: **A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.** *The New England journal of medicine* 2001, **345**(23):1667-1675.
23. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K: **Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.** *Lancet (London, England)* 2003, **362**(9386):772-776.

24. Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR: **Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction**. *Annals of internal medicine* 2004, **141**(9):693-704.
25. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Gupta S *et al*: **Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial**. *Lancet (London, England)* 2009, **374**(9704):1840-1848.
26. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C: **Telmisartan, ramipril, or both in patients at high risk for vascular events**. *The New England journal of medicine* 2008, **358**(15):1547-1559.
27. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P: **Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial**. *Lancet (London, England)* 2008, **372**(9644):1174-1183.
28. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA: **Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial**. *Lancet (London, England)* 2003, **362**(9386):767-771.
29. Maric C, Zheng W, Walther T: **Interactions between angiotensin II and atrial natriuretic peptide in renomedullary interstitial cells: the role of neutral endopeptidase**. *Nephron Physiology* 2006, **103**(3):p149-156.
30. Cruden NL, Fox KA, Ludlam CA, Johnston NR, Newby DE: **Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition**. *Hypertension (Dallas, Tex : 1979)* 2004, **44**(6):913-918.
31. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K *et al*: **Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure**. *New England Journal of Medicine* 2014, **371**(11):993-1004.
32. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J *et al*: **The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial**. *Lancet (London, England)* 2012, **380**(9851):1387-1395.
33. Shibata MC, Flather MD, Wang D: **Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure**. *European journal of heart failure* 2001, **3**(3):351-357.
34. Dargie HJ: **Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial**. *Lancet (London, England)* 2001, **357**(9266):1385-1390.
35. **Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)**. *Lancet (London, England)* 1999, **353**(9169):2001-2007.

36. **The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.** *Lancet (London, England)* 1999, **353**(9146):9-13.
37. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB *et al*: **Effect of carvedilol on survival in severe chronic heart failure.** *The New England journal of medicine* 2001, **344**(22):1651-1658.
38. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL *et al*: **2013 ACCF/AHA Guideline for the Management of Heart Failure.** *A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines* 2013, **128**(16):e240-e327.
39. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E: **Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial.** *American journal of hypertension* 2004, **17**(2):103-111.
40. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C *et al*: **Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.** *Circulation* 2002, **106**(17):2194-2199.
41. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH: **The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.** *The New England journal of medicine* 1996, **334**(21):1349-1355.
42. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vitovec J, Aldershvile J *et al*: **Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF).** MERIT-HF Study Group. *JAMA* 2000, **283**(10):1295-1302.
43. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P *et al*: **Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).** *Eur Heart J* 2005, **26**(3):215-225.
44. Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, Bristow MR, Lavori PW: **A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.** *The New England journal of medicine* 2001, **344**(22):1659-1667.
45. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ *et al*: **Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.** *Lancet (London, England)* 2003, **362**(9377):7-13.
46. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA: **Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.** *The New England journal of medicine* 2004, **351**(6):543-551.
47. de Denus S, White M: **Heart Failure.** In: *RxTx*. 2018.

48. Ezekowitz JA, McAlister FA: **Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials.** *Eur Heart J* 2009, **30**(4):469-477.
49. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B: **Eplerenone in patients with systolic heart failure and mild symptoms.** *The New England journal of medicine* 2011, **364**(1):11-21.
50. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: **The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.** *The New England journal of medicine* 1999, **341**(10):709-717.
51. Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F *et al*: **Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure).** *J Am Coll Cardiol* 2013, **62**(17):1585-1593.
52. Diaz A, Bourassa MG, Guertin MC, Tardif JC: **Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease.** *Eur Heart J* 2005, **26**(10):967-974.
53. Fox K, Ford I, Steg PG, Tendera M, Ferrari R: **Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.** *Lancet (London, England)* 2008, **372**(9641):807-816.
54. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW: **Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure.** *Annals of internal medicine* 2009, **150**(11):784-794.
55. Komajda M, Hanon O, Hochadel M, Lopez-Sendon JL, Follath F, Ponikowski P, Harjola VP, Drexler H, Dickstein K, Tavazzi L *et al*: **Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II.** *Eur Heart J* 2009, **30**(4):478-486.
56. Flannery G, Gehrig-Mills R, Billah B, Krum H: **Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers.** *Am J Cardiol* 2008, **101**(6):865-869.
57. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, Dietz R, Gavazzi A, Van Gilst WH, Hobbs R *et al*: **The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment.** *Eur Heart J* 2003, **24**(5):464-474.
58. DiFrancesco D, Borer JS: **The funny current: cellular basis for the control of heart rate.** *Drugs* 2007, **67 Suppl 2**:15-24.
59. Colin P, Ghaleh B, Monnet X, Su J, Hittinger L, Giudicelli JF, Berdeaux A: **Contributions of heart rate and contractility to myocardial oxygen balance during exercise.** *American journal of physiology Heart and circulatory physiology* 2003, **284**(2):H676-682.
60. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L: **Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.** *Lancet (London, England)* 2010, **376**(9744):875-885.

61. Komajda M, Bohm M, Borer J, Ford I, Krum H, Tase A, Tavazzi L, Swedberg K: **Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure.** *European journal of heart failure* 2013, **15**(1):79-84.
62. JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH *et al*: **Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.** *The New England journal of medicine* 1986, **314**(24):1547-1552.
63. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M *et al*: **A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.** *The New England journal of medicine* 1991, **325**(5):303-310.
64. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R, Jr., Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M *et al*: **Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.** *The New England journal of medicine* 2004, **351**(20):2049-2057.
65. **The effect of digoxin on mortality and morbidity in patients with heart failure.** *The New England journal of medicine* 1997, **336**(8):525-533.
66. Hood WB, Jr., Dans AL, Guyatt GH, Jaeschke R, McMurray JJ: **Digitalis for treatment of heart failure in patients in sinus rhythm.** *The Cochrane database of systematic reviews* 2014(4):CD002901.
67. Teva Canada Limited: **Teva-captopril.** In: *CA Product Monograph.* Toronto, ON; 2021.
68. AMICI Pharmaceuticals LLC: **Captopril.** In: *US Product Monograph.* Melville, NY; 2021.
69. Division of Nephrology & Hypertension: **Adult Drug Book.** In. Louisville, KY: University of Louisville, Division of Nephrology, Kidney Disease Program; 2020.
70. Mosley JD, Shaffer CM, Van Driest SL, Weeke PE, Wells QS, Karnes JH, Velez Edwards DR, Wei WQ, Teixeira PL, Bastarache L *et al*: **A genome-wide association study identifies variants in KCNIP4 associated with ACE inhibitor-induced cough.** *The pharmacogenomics journal* 2016, **16**(3):231-237.
71. Hallberg P, Persson M, Axelsson T, Cavalli M, Norling P, Johansson HE, Yue QY, Magnusson PK, Wadelius C, Eriksson N *et al*: **Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a Swedish population.** *Pharmacogenomics* 2017, **18**(3):201-213.
72. Organon Canada Inc: **Vasotec (enalapril).** In: *CA Product Monograph.* Kirkland, QC; 2021.
73. Bausch Health US LLC: **Vasotec (enalapril).** In: *US Product Monograph.* Bridgewater, NJ; 2020.
74. Pro Doc LTEE: **Fosinopril.** In: *Product Monograph.* Laval, QC; 2018.
75. Rising Pharma Holdings Inc: **Fosinopril.** In: *US Product Monograph.* East Brunswick, NJ; 2021.
76. Teva Pharmaceuticals USA I: **Fosinopril.** In: *US Product Monograph.* North Wales, PA: TEVA PHARMACEUTICALS; 2016.

77. Rxtx: **ACE Inhibitors-CPhA Monograph**. In.: CPhA; 2011.
78. Jin M, Jensen B, Regier L: **Heart Failure (HF): Treatment Overview/Drug and Dosage Considerations**. In: *RxFiles*. Saskatoon Health Region; 2018.
79. McCormack J, Carleton B, Calissi P: **Dosage Adjustment in Renal Impairment**. In: *Therapeutics*. Edited by Jovaisas B. Ottawa (ON): Canadian Pharmacists Association; 2015.
80. Inc. A: **Apo-Fosinopril**. In: *Product Monograph*. Toronto, Ontario: Apotex Inc.; 2016.
81. Canadian Pharmacists Association: **ACE Inhibitors**. In: *CPhA Monograph*. Canadian Pharmacists Association; 2011.
82. Munar MY, Singh H: **Drug dosing adjustments in patients with chronic kidney disease**. *American family physician* 2007, **75**(10):1487-1496.
83. Searchlight Pharma Inc.: **Zestril (lisinopril)**. In: *CA Product Monograph*. Montreal, QC; 2021.
84. Almatica Pharma LLC: **Zestril (lisinopril)**. In: *US Product Monograph*. Morristown, NJ; 2020.
85. Camber Pharmaceuticals Inc: **Lisinopril**. In: *US Product Monograph*. Piscataway, NJ; 2021.
86. Teva Canada Limited: **Teva-lisinopril**. In: *CA Product Monograph*. Toronto, ON; 2019.
87. AstraZeneca Canada Inc: **Zestril (lisinopril)**. In: *CA Product Monograph*. Mississauga, ON; 2017.
88. **Adult Drug Book** In.: University of Louisville, Division of Nephrology, Kidney Disease Program; 2021.
89. Sanis Health Inc: **Perindopril**. In: *CA Product Monograph*. Brampton, ON; 2020.
90. Aurobindo Pharma Limited: **Perindopril**. In: *US Product Monograph*. East Windsor, NJ; 2019.
91. Servier Canada Inc: **Coversyl (perindopril)**. In: *CA Product Monograph*. Laval, Quebec; 2019.
92. Apotex Inc: **Apo-quinapril**. In: *CA Product Monograph*. Toronto, ON; 2019.
93. Parke-Davis Div of Pfizer Inc: **Accupril (quinapril)**. In: *US Product Monograph*. New York, NY; 2021.
94. Inc. P: **pms-Quinapril**. In: *Product Monograph*. Montreal, Quebec: Pharmascience Inc.; 2017.
95. Parke-Davis Div of Pfizer Inc: **Accupril (Quinapril Hydrochloride Tablets )**. In: *US Product Monograph*. NY,NY: Pfizer; 2018.
96. Pfizer Canada Inc: **Accupril**. In. Kirkland, Quebec: Pfizer Canada Inc; 2017.
97. Bausch Health Canada Inc: **Altace (ramipril)**. In: *CA Product Monograph*. Laval, QC; 2021.
98. Pfizer Laboratories Div Pfizer Inc: **Altace (ramipril)**. In: *US Product Monograph*. New York, NY; 2021.

99. Pidlich J, Cichini GM, Reinisch W, Peck-Radosavljevic M, Renner F: **Angiotensin-converting enzyme inhibition in cirrhotic patients--pharmacokinetics of ramipril**. *Acta medica Austriaca* 1997, **24**(1):15-18.
100. PRO DOC LTEE: **Trandolapril**. In: *CA Product Monograph*. Laval, QC; 2022.
101. A-S Medication Solutions: **Trandolapril**. In: *US Product Monograph*. Baltimore, MD; 2021.
102. BGP Pharma ULC: **Mavik (trandolapril)**. In: *CA Product Monograph*. Etobicoke, ON; 2019.
103. Corporation JP: **Jamp-candesartan**. In: *CA Product Monograph*. Boucherville, QC; 2020.
104. Alembic Pharmaceuticals Inc.: **Candesartan cilexetil**. In: *US Product Monograph*. Bridgewater, NJ; 2020.
105. Organon Canada Inc.: **Cozaar (losartan potassium)**. In: *CA Product Monograph*. Kirkland, QC; 2021.
106. Aurobindo Pharma Limited: **Losartan**. In: *US Product Monograph*. East Windsor, NJ; 2021.
107. Sun Pharma Canada Inc.: **Taro-Valsartan**. In: *CA Product Monograph*. Brampton, ON; 2020.
108. Alembic Pharmaceuticals Inc.: **Valsartan**. In: *US Product Monograph*. Bridgewater, NJ; 2021.
109. Brookman LJ, Rolan PE, Benjamin IS, Palmer KR, Wyld PJ, Lloyd P, Flesch G, Waldmeier F, Sioufi A, Mullins F: **Pharmacokinetics of valsartan in patients with liver disease**. *Clinical Pharmacology & Therapeutics* 1997, **62**(3):272-278.
110. Novartis Pharmaceuticals Canada Inc.: **Entresto (sacubitril/valsartan)**. In: *CA Product Monograph*. Dorval, QC; 2021.
111. Novartis Pharmaceuticals Corporation: **Entresto (sacubitril/valsartan)**. In: *US Product Monograph*. East Hanover, NJ; 2021.
112. Mint Pharmaceuticals Inc: **Mint-bisoprolol**. In: *CA Product Monograph*. Mississauga, ON; 2021.
113. Novitium Pharma LLC: **Bisoprolol fumarate**. In: *US Product Monograph*. East Windsor, NJ; 2021.
114. Sanis Health Inc.: **Bisoprolol**. In: *CA Product Monograph*. Brampton, ON; 2020.
115. Alembic Labs LLC: **Bisoprolol**. In: *US Product Monograph*. West Caldwell, NJ; 2020.
116. Hayes PC, Jenkins D, Vavianos P, Dagap K, Johnston A, Ioannides C, Thomas P, Williams R: **Single oral dose pharmacokinetics of bisoprolol 10 mg in liver disease**. *Eur Heart J* 1987, **8 Suppl M**:23-29.
117. Auro Pharma Inc.: **Auro-carvedilol**. In: *CA Product Monograph*. Woodbridge, ON; 2021.
118. Aurobindo Pharma Limited: **Carvedilol**. In: *US Product Monograph*. East Windsor, NJ; 2021.
119. GlaxoSmithKline LLC: **Coreg CR (carvedilol phosphate capsule extended release)**. In: *US Product Monograph*. Research Triangle Park, NC; 2020.



120. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ *et al*: **Pharmacogenetics: from bench to byte--an update of guidelines**. *Clin Pharmacol Ther* 2011, **89**(5):662-673.
121. **Dutch Guidelines**. [<https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf>]
122. Novartis Pharmaceuticals Canada Inc.: **LOPRESOR (metoprolol tartrate)**. In: *CA Product Monograph*. Dorval, QC; 2020.
123. Youngtech Pharmaceuticals Inc.: **Metoprolol tartrate tablet**. In: *US Product Monograph*. Cranbury, NJ; 2020.
124. BluePoint Laboratories: **Metoprolol succinate ER tablets**. In: *US Product Monograph*. Springdale, AR; 2021.
125. Sun Pharmaceutical Industries Inc.: **Metoprolol succinate capsule extended release**. In: *US Product Monograph*. New Brunswick, NJ; 2020.
126. Pharmascience Inc: **Pms-metoprolol-I**. In: *Canadian Product Monograph*. Montreal, QC; 2020.
127. Aralez Pharmaceuticals US Inc: **Torprol XL (metoprolol succinate)**. In: *US Product Monograph*. Parsippany, NJ; 2019.
128. Validus Pharmaceuticals LLC: **Lopressor (metoprolol tartrate)**. In: *US Product Monograph*. Parsippany, NJ; 2019.
129. Mint Pharmaceuticals Inc: **Mint-eplerenone**. In: *CA Product Monograph*. Mississauga, ON; 2021.
130. Westminster Pharmaceuticals LLC: **Eplerenone**. In: *US Product Monograph*. Nashville, TN; 2021.
131. Upjohn Canada ULC: **Inspira (eplerenone)**. In: *CA Product Monograph*. Kirkland, QC; 2020.
132. GDSearlePfizer: **Inspira (eplerenone)**. In: *USA product monograph*. NY, NY: G.D. Searle LLC Division of Pfizer Inc; 2018.
133. AHFS: **Eplerenone**.
134. Mint Pharmaceuticals Inc: **Mint-spironolactone**. In: *CA Product Monograph*. Mississauga, ON; 2020.
135. Aurobindo Pharma Limited: **Spironolactone**. In: *US Product Monograph*. East Windsor, NJ; 2021.
136. Mint Pharmaceuticals Inc: **Mint-Spironolactone**. In: *CA Product Monograph*. Mississauga, ON; 2019.
137. GD Searle LLC: **Aldactone (spironolactone)**. In: *US Product Monograph*. NY, NY; 2020.
138. **Adult Drug Book**. In.: University of Louisville, Division of Nephrology, Kidney Disease Program; 2020.
139. AstraZeneca Canada Inc: **Forxiga (dapagliflozin)**. In: *CA Product Monograph*. Mississauga, ON; 2021.

140. AstraZeneca Pharmaceuticals LP: **Farxiga (dapagliflozin)**. In: *US Product monograph*. Wilmington, DE; 2021.
141. Canada A: **Forxiga (dapagliflozin)**. In: *CA Product Monograph*. 2020.
142. AstraZeneca: **Farxiga (dapagliflozin)**. In: *US Product monograph*. 2020.
143. Boehringer Ingelheim (Canada) Ltd: **Jardiance (empagliflozin)**. In: *CA Product Monograph*. Burlington, ON; 2021.
144. Boehringer Ingelheim Pharmaceuticals Inc: **Jardiance (empagliflozin)**. In: *US Product Monograph*. Ridgefield, CT; 2021.
145. Boehringer\_Ingelheim\_Pharmaceuticals IC: **Jardiance (Empagliflozin)**. In: *CA Product Monograph*. 2020.
146. Boehringer\_Ingelheim\_Pharmaceuticals IU: **Jardiance (Empagliflozin)**. In: *FDA Product Monograph*. Ridgefield, CT; 2020.
147. Mint Pharmaceuticals Inc: **Mint-Hydralazine**. In: *CA Product Monograph*. Mississauga, ON; 2017.
148. Cadila Pharmaceuticals Limited: **Hydralazine**. In: *US Product Monograph*. Ahmedabad, Gujarat, INDIA; 2021.
149. Cheng JWM: **A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination**. *Clinical Therapeutics* 2006, **28**(5):666-678.
150. Rxtx: **Hydralazine**. In: *CPhA monograph*. 2014.
151. RxFiles: **Thiazide-Like Diuretics**. In: *RxFiles Drug Comparison Charts*. Edited by Regier L, Jensen B, vol. 2017. Saskatoon, SK: Saskatoon Health Region; 2017.
152. AA Pharma Inc: **Isosorbide Dinitrate**. In: *CA Product Monograph*. Vaughan, ON; 2010.
153. Par Pharmaceutical Inc: **Isosorbide dinitrate**. In: *US Product Monograph*. Chestnut Ridge, NY; 2021.
154. Servier Canada Inc: **Lancora (ivabradine)**. In: *CA Product Monograph*. Laval QC; 2018.
155. Amgen Inc: **Corlanor (ivabradine)**. In: *US Product Monograph*. Thousand Oaks, CA; 2021.
156. (digoxin) T: **Toloxin (digoxin)**. In: *CA Product Monograph*. Montreal, QC; 2021.
157. Novitium Pharma LLC: **Digoxin**. In: *US Product Monograph*. East Windsor, NJ; 2021.
158. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL *et al*: **2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines**. *J Am Coll Cardiol* 2013, **62**(16):e147-239.
159. Merck Sharp & Dohme Corp.: **Verquvo (vericiguat)**. In: *US Product Monograph*. Whitehouse Station, NJ; 2021.